AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28981381 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (180 mg EPA, 120 mg DHA) supplementation (1 g/day for 4 weeks)
Number of subjects: 60
Study 27033358 — intervention group
Group type: COMPARATOR
Intervention: Contact-force catheter
Number of subjects: 268
Study 27033358 — intervention group
Group type: COMPARATOR
Intervention: Flexible-tip catheter
Number of subjects: 268
Study 27033358 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional catheter
Number of subjects: 268
Study 27033358 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear lesions and CFAEs ablation
Number of subjects: 268
Study 24172725 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Stockings (CS)
Number of subjects: 10
Study 23338256 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% NaOCl solution
Number of subjects: 20
Study 23338256 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA solution
Number of subjects: 20
Study 23338256 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% NaOCl and 17% EDTA
Number of subjects: 20
Study 23338256 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 20
Study 19834314 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich antioxidant supplement containing pomegranate extract, green tea extract, and ascorbic acid
Number of subjects: 114
Study 18468839 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized furosemide
Number of subjects: 0
Study 16363622 — intervention group
Group type: EXPERIMENTAL
Intervention: 18FDG-PET
Number of subjects: 44
Study 16363622 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 18FDG-PET and bone scintigraphy
Number of subjects: 44
Study 16363622 — intervention group
Group type: COMPARATOR
Intervention: Bone scintigraphy
Number of subjects: 44
Study 12398236 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-breakfast C-peptide levels <= 0.8 nmol/l
Number of subjects: 118
Study 12398236 — intervention group
Group type: COMPARATOR
Intervention: Post-breakfast C-peptide levels > 0.8 nmol/l
Number of subjects: 118
Study 12398236 — intervention group
Group type: COMPARATOR
Intervention: GADA+ subjects
Number of subjects: 118
Study 12398236 — intervention group
Group type: COMPARATOR
Intervention: Hypoglycemic agents and/or diet
Number of subjects: 118
Study 9884259 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir (800 mg q.i.d.)
Number of subjects: 101
Study 9884259 — intervention group
Group type: COMPARATOR
Intervention: Oral ganciclovir (1000 mg t.i.d.)
Number of subjects: 101
Study 9884259 — intervention group
Group type: COMPARATOR
Intervention: Oral acyclovir vs. ganciclovir in D+R- patients
Number of subjects: 101
Study 9884259 — intervention group
Group type: COMPARATOR
Intervention: Oral acyclovir vs. ganciclovir in D+R+ patients
Number of subjects: 101
Study 9884259 — intervention group
Group type: COMPARATOR
Intervention: Oral acyclovir vs. ganciclovir in D-R+ patients
Number of subjects: 101
Study 7898300 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention designed to improve probabilistic diagnostic judgments
Number of subjects: 515
Study 7898300 — intervention group
Group type: COMPARATOR
Intervention: Standard lecture (control intervention)
Number of subjects: 515
Study 2677725 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (600 units per kilogram of body weight) intravenously twice a week for 21 days
Number of subjects: 47
Study 2677725 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenously twice a week for 21 days
Number of subjects: 47
Study 2677725 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 47
Study 2677725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 416989 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacilli preparation (Lactinex)
Number of subjects: 50
Study 416989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30506495 — intervention group
Group type: EXPERIMENTAL
Intervention: CJ‐40001 (test formulation)
Number of subjects: 0
Study 30506495 — intervention group
Group type: COMPARATOR
Intervention: NESP® (reference formulation)
Number of subjects: 0
Study 30580705 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderzone infarcts
Number of subjects: 101
Study 30580705 — intervention group
Group type: EXPERIMENTAL
Intervention: Core middle cerebral artery infarcts
Number of subjects: 101
Study 30580705 — intervention group
Group type: EXPERIMENTAL
Intervention: Perforator infarcts
Number of subjects: 101
Study 30580705 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderzone infarcts with impaired collateral flow
Number of subjects: 101
Study 30580705 — intervention group
Group type: EXPERIMENTAL
Intervention: Collateral flow assessment
Number of subjects: 101
Study 27138652 — intervention group
Group type: EXPERIMENTAL
Intervention: Oritavancin 1600 mg IV over 3 hours
Number of subjects: 150
Study 27138652 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg oral
Number of subjects: 150
Study 27138652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 24321697 — intervention group
Group type: EXPERIMENTAL
Intervention: Use in negative affective situations
Number of subjects: 87
Study 24321697 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping with negative affect as a target in treatments for marijuana dependence
Number of subjects: 87
Study 21215605 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bread with added plant sterols (2g/d)
Number of subjects: 68
Study 21215605 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bread with added plant sterols (4g/d)
Number of subjects: 68
Study 21215605 — intervention group
Group type: COMPARATOR
Intervention: Control group (rye bread without plant sterols)
Number of subjects: 68
Study 19854119 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding support team intervention (hospital visits, home visits, telephone support, 24-hour pager access)
Number of subjects: 328
Study 19854119 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group (standard care)
Number of subjects: 328
Study 19854119 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding support team intervention
Number of subjects: 328
Study 19854119 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 328
Study 17010149 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 41
Study 15567813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural bupivacaine 0.25%
Number of subjects: 41
Study 15567813 — intervention group
Group type: COMPARATOR
Intervention: Intrapleural saline
Number of subjects: 41
Study 11814497 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Misoprostol
Number of subjects: 573
Study 11814497 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Misoprostol
Number of subjects: 573
Study 11814497 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone
Number of subjects: 573
Study 11814497 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 573
Study 10417864 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 14
Study 7729296 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral magnesium therapy (30 mmol/day)
Number of subjects: 40
Study 7729296 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 40
Study 2200300 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol administered at a temperature of 4 degrees C
Number of subjects: 0
Study 2200300 — intervention group
Group type: COMPARATOR
Intervention: Propofol administered at standard temperature (not specified)
Number of subjects: 0
Study 6111671 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B surface antigen vaccine
Number of subjects: 138
Study 6111671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 30519818 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg, three times a day for 5 days)
Number of subjects: 112
Study 30519818 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three times a day for 5 days)
Number of subjects: 112
Study 27874176 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training (3 weeks center-based and 12 weeks home-based, 50 minutes per session, 3 times per week)
Number of subjects: 66
Study 27874176 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training
Number of subjects: 66
Study 25862012 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) 50 mg twice daily
Number of subjects: 16
Study 25862012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 25293351 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (400 mg daily)
Number of subjects: 261
Study 22089249 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium diet (>200 mmol of sodium per day)
Number of subjects: 39
Study 22089249 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet (<10 mmol/d)
Number of subjects: 39
Study 20832062 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 36
Study 20832062 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 36
Study 17071935 — intervention group
Group type: EXPERIMENTAL
Intervention: GV plus CDDP 50 mg/m(2) on days 1 and 8 (PGV arm)
Number of subjects: 433
Study 17071935 — intervention group
Group type: EXPERIMENTAL
Intervention: GT plus CDDP 50 mg/m(2) on days 1 and 8 (PGT arm)
Number of subjects: 433
Study 17071935 — intervention group
Group type: COMPARATOR
Intervention: GEM 1000 mg/m(2) and PTX 125 mg/m(2) on days 1 and 8 (GT arm)
Number of subjects: 433
Study 17071935 — intervention group
Group type: COMPARATOR
Intervention: GEM 1000 mg/m(2) and VNR 25 mg/m(2) on days 1 and 8 (GV arm)
Number of subjects: 433
Study 15683661 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular brachytherapy (18 Gy prescribed 2 mm from the surface of centering balloons)
Number of subjects: 134
Study 15683661 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham irradiation)
Number of subjects: 134
Study 11872412 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin petrolatum (0.1 cc/25 cm2)
Number of subjects: 35
Study 11872412 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick petrolatum (0.3 cc/25 cm2)
Number of subjects: 35
Study 11872412 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin salicylic acid (20%) in petrolatum
Number of subjects: 35
Study 11872412 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick salicylic acid (20%) in petrolatum
Number of subjects: 35
Study 11872412 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen
Number of subjects: 35
Study 10458175 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 2.5 mg of dexamethasone disodium phosphate
Number of subjects: 50
Study 7581970 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg of Pyridostigmine (PST)
Number of subjects: 6
Study 7581970 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of Pyridostigmine (PST)
Number of subjects: 6
Study 7581970 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg of Pyridostigmine (PST)
Number of subjects: 6
Study 7581970 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of octreotide (SMS)
Number of subjects: 6
Study 7581970 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS + TRH
Number of subjects: 6
Study 7581970 — intervention group
Group type: EXPERIMENTAL
Intervention: PST + SMS + TRH
Number of subjects: 6
Study 7581970 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of TRH
Number of subjects: 6
Study 7581970 — intervention group
Group type: COMPARATOR
Intervention: TRH-induced TSH response
Number of subjects: 6
Study 2372011 — intervention group
Group type: EXPERIMENTAL
Intervention: Accutracker ambulatory blood pressure monitor
Number of subjects: 120
Study 7017170 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 125
Study 7017170 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl‐chloroethyl‐cyclohexy‐nitrosourea
Number of subjects: 125
Study 7017170 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 125
Study 7017170 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 125
Study 31678452 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 206
Study 31678452 — intervention group
Group type: EXPERIMENTAL
Intervention: Goreisan
Number of subjects: 206
Study 31678452 — intervention group
Group type: COMPARATOR
Intervention: Nonadministration
Number of subjects: 206
Study 31119717 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral physical activity intervention (introductory personal training session followed by eight weekly 15-min PA behavioral coaching sessions)
Number of subjects: 28
Study 31119717 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral physical activity intervention
Number of subjects: 28
Study 27901413 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground training with stimulation (OG)
Number of subjects: 64
Study 27901413 — intervention group
Group type: COMPARATOR
Intervention: Treadmill-based training with manual assistance (TM)
Number of subjects: 64
Study 27901413 — intervention group
Group type: COMPARATOR
Intervention: Treadmill-based training with stimulation (TS)
Number of subjects: 64
Study 27901413 — intervention group
Group type: COMPARATOR
Intervention: Treadmill-based training with locomotor robotic device assistance (LR)
Number of subjects: 64
Study 25893544 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE) 4 grams/day
Number of subjects: 849
Study 25893544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 849
Study 23927847 — intervention group
Group type: EXPERIMENTAL
Intervention: HP802‐247 (cell therapy)
Number of subjects: 183
Study 23927847 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 183
Study 21181447 — intervention group
Group type: COMPARATOR
Intervention: HRQoL measures using SF-6D, EQ-5D, QWB-SA, HUI2, HUI3
Number of subjects: 3578
Study 21181447 — intervention group
Group type: COMPARATOR
Intervention: EQ-5D
Number of subjects: 3578
Study 21181447 — intervention group
Group type: COMPARATOR
Intervention: HRQoL measures
Number of subjects: 3578
Study 19627215 — intervention group
Group type: EXPERIMENTAL
Intervention: BF-7
Number of subjects: 46
Study 19627215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 16914379 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly nurse‐led lifestyle counselling (N=31)
Number of subjects: 51
Study 16914379 — intervention group
Group type: COMPARATOR
Intervention: Conventional primary care (N=20)
Number of subjects: 51
Study 16970865 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent management training program (10 sessions)
Number of subjects: 24
Study 16970865 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 24
Study 14632622 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-selected mobilisation technique
Number of subjects: 140
Study 14632622 — intervention group
Group type: COMPARATOR
Intervention: Randomly selected mobilisation technique
Number of subjects: 140
Study 10971302 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg lamotrigine once daily for 6 days
Number of subjects: 20
Study 10971302 — intervention group
Group type: COMPARATOR
Intervention: 2 g lithium gluconate anhydrous every 12 h for 5 days and in the morning of day 6
Number of subjects: 20
Study 8971501 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (1.2 g alcohol/kg of body weight)
Number of subjects: 8
Study 8971501 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 8
Study 1534831 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 100
Study 1534831 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide and amiloride (Moduretic)
Number of subjects: 100
Study 3898481 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mOsm/L hypotonic solution
Number of subjects: 0
Study 3898481 — intervention group
Group type: COMPARATOR
Intervention: 300 mOsm/L isotonic solution
Number of subjects: 0
Study 30977397 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (n = 18)
Number of subjects: 43
Study 30977397 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric moderate-intensity continuous training (n = 19)
Number of subjects: 43
Study 28526223 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute cord clamping
Number of subjects: 0
Study 28526223 — intervention group
Group type: COMPARATOR
Intervention: 1-minute cord clamping
Number of subjects: 0
Study 25525191 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg)
Number of subjects: 28
Study 25525191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 23069874 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (n = 43)
Number of subjects: 86
Study 23069874 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 38)
Number of subjects: 86
Study 21240162 — intervention group
Group type: EXPERIMENTAL
Intervention: Inj. Aprotinin
Number of subjects: 90
Study 21240162 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranaexaemic Acid
Number of subjects: 90
Study 21240162 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon Amino Caproic Acid (EACA)
Number of subjects: 90
Study 18971533 — intervention group
Group type: EXPERIMENTAL
Intervention: Nattokinase (2,000 FU/capsule) for 8 weeks
Number of subjects: 86
Study 18971533 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule for 8 weeks
Number of subjects: 86
Study 17674310 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV) only
Number of subjects: 191
Study 17674310 — intervention group
Group type: COMPARATOR
Intervention: Oral poliovirus vaccine (OPV) only
Number of subjects: 191
Study 14687053 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide
Number of subjects: 300
Study 14687053 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 300
Study 14687053 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline plus lignocaine
Number of subjects: 300
Study 11679461 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes diagnosed by fasting plasma glucose (FPG) > or =7.0 mmol/l
Number of subjects: 5400
Study 11679461 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes diagnosed by isolated postchallenge hyperglycemia (IPH) (FPG <7.0 mmol/l and 2-h plasma glucose concentration > or =11.1 mmol/l)
Number of subjects: 5400
Study 11679461 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes diagnosed by IPH at baseline
Number of subjects: 5400
Study 11679461 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes diagnosed by FPG at baseline
Number of subjects: 5400
Study 9815533 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli supplements, 3 g/day
Number of subjects: 29
Study 9815533 — intervention group
Group type: COMPARATOR
Intervention: No cruciferous vegetables (Control)
Number of subjects: 29
Study 8267146 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine group (n = 25) received 2 mL of 0.5% tetracaine (10 mg) containing clonidine (0.15 mg)
Number of subjects: 75
Study 8267146 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine group (n = 25) received 2 mL of 0.5% tetracaine (10 mg) containing phenylephrine (3 mg)
Number of subjects: 75
Study 8267146 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 25) received 2 mL of 0.5% tetracaine (10 mg) alone
Number of subjects: 75
Study 3300834 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 72
Study 3300834 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine
Number of subjects: 72
Study 3300834 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of D-penicillamine and chloroquine
Number of subjects: 72
Study 3300834 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine alone
Number of subjects: 72
Study 30279267 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg, intravenously every 2 weeks for 12 weeks)
Number of subjects: 27
Study 30279267 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenously every 2 weeks for 12 weeks)
Number of subjects: 27
Study 30279267 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 27
Study 30279267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 30279267 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab and Placebo
Number of subjects: 27
Study 26787799 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal softening of double-lumen endobronchial tubes (DLTs) in warm saline at 40°C for 10 min
Number of subjects: 140
Study 25680893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose (LD)/90 mg bid maintenance dose (MD)
Number of subjects: 56
Study 25680893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 56
Study 25680893 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 600 mg LD/150 mg MD
Number of subjects: 56
Study 23815535 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 70
Study 23815535 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol succinate
Number of subjects: 70
Study 20861128 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with HF
Number of subjects: 205
Study 20861128 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic patients with HF
Number of subjects: 205
Study 18647232 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 120 mg day(-1) for 6 months
Number of subjects: 40
Study 18647232 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 40
Study 17050867 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan 60 mg/m2 and docetaxel 35 mg/m2 with celecoxib 400 mg twice daily
Number of subjects: 133
Study 17050867 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan 100 mg/m2 and gemcitabine 1,000 mg/m2 with celecoxib 400 mg twice daily
Number of subjects: 133
Study 17050867 — intervention group
Group type: COMPARATOR
Intervention: irinotecan 60 mg/m2 and docetaxel 35 mg/m2 without celecoxib
Number of subjects: 133